The purpose of this study is to evaluate whether NPC-08 is safety and efficacy in the treatment of newly-diagnosed malignant glioma and recurrent glioblastoma multiforme.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
24
Polifeprosan 20 with Carmustine 3.85%
The Tazuke Kofukai Foundation Medical Research Kitano Hospital
Osaka, Osaka, Japan
Overall survival to 12 months
Time frame: 12 months
Progression-free survival
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.